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ABSTRACT 
Hyperlipidemia is major problem among population those, who have sedentary life style. The effects of ethanolic and aqueous root extract of 
Rubiacordifoliain experimentally induced hyperlipidemic rats were investigated. 42 wistar rats of both sexes were used for the study. The 
animals were completely randomized into seven groups comprising 6 animals each. The groups were treated as follows: Group I: normal diet 
(ND); Group II: HFD ( Vanaspati ghee + coconut oil mixture in ratio of 3:2 at 10 ml/kg/day); Group III: HFD + Atorvastatin (10 mg/kg/day); 
Group IV: HFD+ ethanolic extract of roots of Rubia cordifolia low dose(200 mg/kg/day); Group V: HFD + ethanolic extract of roots of Rubia 
cordifolia high dose (400 mg/kg/day); Group VI: HFD + aqueous extract of roots of Rubia cordifolia low dose (200 mg/kg/day); Group VII: HFD + 
aqueous extract of roots of Rubia cordifolia high dose (400 mg/kg/day). Hypercholesterolemia was induced by feeding the animals with high fat 
diet for 21 days before administration of the extract. After 21thday of feeding, administration of extract lasted for 14 days. Preliminary 
phytochemical screening revealed that the ethanolic and aqueous root extract of Rubia cordifolia contains glycosides, triterpenoids, saponins, 
alkaloids and flavonoids. Overall, findings from the present study suggest that the antihyperlipidemic activity observed with Atorvastatin 
(10mg/kg oral) and the ethanolic extracts of Rubia cordifolia (400mg/kg) showed better activity thanaqueous extracts of Rubia cordifolia 
(200mg/kg). 
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1. INTRODUCTION 
Hyperlipidemia is caused by overabundance of lipids or fatty 
substances in the blood and is an important risk factor in 
development of atherosclerosis and heart diseases.1 
Hyperlipidemia may be caused by genetic factors or by 
generalized metabolic disorders like diabetes mellitus, 
excessive alcohol intake, hypothyroidism or primary biliary 
cirrhosis. Alteration in cholesterol 2  triglyceride very low-
density lipoproteins (VLDL), low-density lipoproteins (LDL) 
and intermediate density lipoproteins (IDL), which are 
different forms of lipids, responsible for possible 
complications in human body such as acute pancreatitis, 
occlusion of blood vessels and reduced elasticity of the 
lumen of the artery.3 Moreover risk increases with diabetes 
mellitus, hypothyroidism, nephrosis, alcoholism, of oral 
contraceptives, family history of hyperlipidemia,4,5 and 
improper diet that is high in fat and cholesterol. Though 
drugs therapies available for the treatment of 
hyperlipidemia includes use of drugs like Niacin, Fibrates 
(Clofibrate, Gemfibrozil), HMG-CoA reductase inhibitors 
(Lovastatin, Pravastatin, Simvastatin,6 and Fluvastatin), Bile 
acid binding resins (Cholestyramine and Cholestipol) and 
Probucol but associated with lots of side effects.7,8 Therefore, 
herbal treatment for hyperlipidemia has been appreciated 
because of no side effects, economic and easy availablility. 
Herbal drugs involved in the treatment of hyperlipidemia are 
Allium sativum, Allium cepa, Bosswellia serrata, Brassica 
vercapitata, Commiphora mukul, Garcinia cambogia, Glycine 
max, Phyllanthus niruri, Moringa olifera,9,10 Saururu 
schinensis, Curcuma loga, Terminalia arjuna, Acorus calamus, 
Liriopeplatyphylla, Citrus, Hibiscuss abdariffa, Schisandrin B, 
ShanZha, Ulva Pertusa, Picrorrhiza rhizoma.4,11,12  
2. MATERILS AND METHODS 
2.1. Material 
2.1.1. Plant materials and authentication 
Roots of Rubia cordifolia Linn, (2kg) were collected from 
local area supplier of Delhi, during the month of October 
2015. Sample of plant material was sent to the Department 
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of Botany, National Institute of Science Communication and 
Information Resources, (NISCAIR) Delhi-110011, for 
identification and taxonomic authentication 
2.2.2 Experimental Animals 
Wistar rat of either sex, weighing 150-250g purchased from 
All India Institute of Medical Sciences animal house, New 
Delhi. All test animals were allowed free access to food and 
water ad libitum, both being withdrawn just prior to 
experimentation. 
2.2 Methods 
2.2.1. Preparation of plant extract of Rubia cordifolia 
The authenticated roots of Rubia cordifolia was collected and 
subjected to shade drying. The size were reduced and made 
to coarse powder and then further passed through the 
appropriate sieve no. to obtain uniform particle size. The 
powdered root was extracted with ethanol and water by 
using soxhlet apparatus. The root extracts were filtered, 
collected, and concentrated by using Rotatory Flash 
Evaporator. The extracts were used for the further 
experimental models. 
2.2.2. Determination of Body Weight 
The weight of individual rat of each group was measured 
‘only’ before and ‘after’ administration of extract. 
2.3. Animal grouping, feeding and extract 
administration 
2.3.1. Experimental design:  
Animals were fasted for 24 hours before the experiment with 
free access to water.  
2.3.2. Preparation of drugs  
The ethanolic extract of root of Rubia cordifolia was 
suspended in 2% Tween-80 and used for oral 
administration. Each time fresh preparations of the extracts 
were prepared.  
2.3.3. Assessment of antihyperlipidemic activity  
MODEL- High Fat Diet (HFD) induced hyperlipidemic model 
used for study. 
Preparation of Feed 
Normal animal food pellets were crushed in mortar and 
pestle to crush into small pieces and then grinded into fine 
powder in mixer grinder. The other ingredients i.e. 
cholesterol 2% , cholic acid 1% , sucrose 40% , and coconut 
oil 10% were added in the mixer grinder in an ascending 
order of their quantity and mixed well. This dried powder 
was then mixed with same quantity of water every time to 
make small balls of feed and later this was stored in self 
sealing plastic covers in refrigerator at 2°C to 8°C. The feed 
for normal group was prepared similarly by grinding only 
the normal food pellets and then mixed with water without 
the other excipients. This preparation of feed was done once 
in three days for all the animals. 42 Wistar rats were 
randomly divided into seven groups each group containing 
six animals. The chronic hyperlipidemia was produced by 
feeding the above prepared food for 21 days. The rats were 
then given ethanolic and aqueous root extract of Rubia 
cordifolia(200 and 400 mg/kg, oral) and Atorvastatin (10 
mg/kg, oral) once daily in the morning. 
  
Table 1: Classification of groups according to their doses 
Group N Treatment Dose 
Group I 6 Normal saline 10ml/kg  body weight 
Group II 6 High fat diet  
Group III 6 High fat diet+ Atorvastatin 10 mg/kg body weight 
Group IV 6 Rubia cordifolia ethanolic root  extract of low dose+HFD 200 mg/kg body weight 
Group V 6 Rubia cordifolia ethanolic root  extract of high dose+HFD 400 mg/kg body weight 
Group VI 6 Rubia cordifolia aqueous root extract of low dose+ HFD 200 mg/kg body weight 
Group VII 6 Rubia cordifolia aqueous root extract of high dose+ HFD 400 mg/kg body weight 
N= Number of animals in each group                     HFD= High fat diet 
On the day 21th, animals were anaesthetized with chloroform 
and blood was collected by tail vein. The blood samples were 
centrifuged for 15 min at 2500rpm to obtain serum. The 
collected serum was analyzed for serum Total Cholesterol, 
Triglycerides, High Density Lipoprotein Cholesterol, Low 
Density Lipoprotein Cholesterol and Very Low Density 
Lipoprotein Cholesterol. 
2.4. Evaluation of antioxidant activity 
The antioxidant property of Rubia cordifolia roots extracts 
were studied by the following methods 
 Determination of total phenolic content  
 
Determination of the total antioxidant capacity  
Table 2: Total phenol content of roots extract of Rubia cordifolia plant 
Sample Total Phenol Contents (mg/g) 
Aqueous extract of Rubia cordifolia root 380.2 
Ethanolic extract of Rubia cordifolia root 413.6 
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3. RESULTS 
3.1. Antihyperlipidemic activity of ethanolic and aqueous root extracts of Rubia cordifolia 
Table 3: Effects of ethanolic and aqueous extracts of roots of Rubia cordifolia on body weight HFD induced hyperlipidemic rats. 
…... 
….. 
…Day 
Mean Body weight (gm)(% change in body weight) 
Normal HCD STD Eth.200 
EERC 
mg/kg 
Eth.400 
EERC 
mg/kg 
Aqu.200 
AERC 
mg/kg 
Aqu.400 
AERC 
mg/kg 
0th day 148.33 138.66 146.33 144.83 144.44 145.00 146.66 
5th day 161.33 
(↑8.76) 
164.66 
(↑18.75) 
165.33 
(↑12.98) 
166.50 
(↑14.96) 
167.44 
(↑15.92) 
170.50 
(↑17.58) 
169.66 
(↑15.68) 
10th day 169.10 
(↑14.00) 
179.66 
(↑29.56) 
181.66 
(↑24.14) 
181.00 
(↑24.97) 
180.00 
(↑24.61) 
182.66 
(↑25.97) 
179.00 
(↑22.05) 
15th day 178.33 
(↑20.22) 
187.33 
(↑35.10) 
189.53 
(↑29.72) 
188.00 
(↑29.80) 
185.33 
(↑28.30) 
190.00 
(↑31.03) 
183.53 
(↑25.13) 
20th day 183.66 
(↑23.81) 
199.33 
(↑44.09) 
192.33 
(↑31.43) 
192.66 
(↑33.02) 
190.33 
(↑31.77) 
195.33 
(↑34.71) 
194.66 
(↑32.72) 
Values are Mean ± S.E.M. (n=6); Significance vs. Control group: ***P < 0.001, **P < 0.01 and *P < 0.05, using one- way ANOVA followed by 
Dunnett’s t test.                  (EERC) Ethanolic extracts of roots of Rubiacordifolia     (AERC) Aqueous extracts of roots of Rubiacordifolia 
 
 
Figure 1: Effect of the ethanolic and aqueous root extract of Rubiacordifolia on serum lipid profile levels (mg/dL) at 0th, 5th, 10th, 
15thand 20th day in HFD induced wistar rats. 
 
Table 4: Various parameters of antihyperlipidemic activity in wistar rats, using ethanolic and aqueous root extracts of Rubia 
cordifolia. 
Group 
…No 
Treatment TC 
(mg/dl) 
TG 
(mg/dl) 
HDL 
(mg/dl) 
VLDL 
(mg/dl) 
LDL 
(mg/dl) 
I Normal 77.77± 4.05 70.15± 6.16 34.81± 1.58 14.03± 1.23 27.08± 2.91 
II HCD 183.33 ±6.67 
(↑    135.73) 
148.92± 6.53 
(↑112.28) 
18.51± 1.36 
↓46.82 
29.77± 1.30 
(↑112.18) 
135.04± 5.47 
(↑1041.40) 
III HCD+Atorva. 
(10mg/kg) 
103.33±7.13* 
(↓43.64) 
97.22± 5.28* 
(↓34.71) 
31.47± 2.54* 
(↑70.01) 
19.60±1.03* 
(↓34.16) 
51.80± 3.97* 
(↓61.64) 
IV HCD + 
Eth.(200mg/kg) 
150.0±10.33* 
(↓18.19) 
121.54±3.29* 
(↓18.38) 
25.92± 1.58* 
(↑40.03) 
24.41±0.75* 
(↓18.00) 
99.77± 9.85* 
(↓26.57) 
V HCD + 
Eth.(400mg/kg) 
128.33± 6.01* 
(↓30.00) 
112.74±5.56* 
(↓24.29) 
28.10± 2.19* 
(↑51.80) 
22.51±1.12* 
(↓24.38) 
77.67± 3.97* 
(↓42.48) 
VI HCD + 
Aqu.(200mg/kg) 
153.33±7.60* 
(↓16.37 ) 
124.36±6.05* 
(↓16.49) 
22.58± 1.66 
(↑21.98) 
24.86±1.21* 
(↓16.49) 
105.96 ±6.06 
(↓21.53) 
VII HCD + 
Aqu.(400mg/kg) 
146.66± 6.15* 
(↓20.01) 
119.60±7.54* 
(↓19.68) 
26.65± 1.72* 
(↑43.97) 
23.86±1.52* 
(↓19.85) 
96.15± 4.88* 
(↓28.79) 
All values were expressed as Mean ± SEM, n.s. (non significant) as compared to vehicle control group. 
-test. 
up (i.e., group I), ANOVA followed by Dunnett’s t-test. 
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Figure 2: Effect of ethanolic and aqueous extract of Rubia 
cordifoliaon concentrations of TC, TG, HDL, VLDL, and LDL, of 
rats fed high fat containing diet. The values were are mean ± 
S.E.M. for six rats. Groups’ I with II and III, IV, V, VI, VII were 
are compared with Group II, ** p<0.01, * p<0.05. 
 
Statistical Analysis 
Results were expressed as mean ± SEM. Difference among 
data were determined using statistics express lite software.  
The data obtained from antihyperlipidemic study was 
subjected to one-way ANOVA, followed by Dunnett’s t test 
for statistical significance P<0.001,P<0.05  and P<0.01 is 
considered to be statically significant. 
4. DISCUSSION 
Plants have formed the basis of sophisticated traditional 
medicine system and natural products make excellent leads 
for new drug development. The World Health Organization 
(WHO) is encouraging, promoting and facilitating the 
effective use of herbal medicine in developing countries for 
health problems. Plant have been used as medicines for 
thousands of years and are used today in their natural form 
as well as processed from many medicinal plants. The 
importance of plants has been forgotten by modern man as a 
result of his dependence on the quick   result of allopathic 
medicines. Plant drugs are being rediscovered because of 
growing awareness of unwanted side effects. The plant has 
been chosen for this study as it was easily available and has 
various pharmacological activities with their scientific 
evidences. 
42 Wistar rats were randomly divided into 7 groups of six 
each. The chronic experimental hyperlipidemia was 
produced by feeding the above prepared food for 21 days. 
The rats were then given test plant extracts i.e., Rubia 
cordifolia ethanolic and aqueous root extracts (200 and 400 
mg/kg, oral) and Atorvastatin (10 mg/kg, oral) once daily in 
the morning. The result have revealed that keeping the 
animal on HFD significantly increased the TC, TG, LDL-C level 
in serum (P<0.05) as compared to rats on normal diet. When 
HFD was co-administered with Rubia cordifolia extracts, the 
elevated levels of TC, TG and LDL-C condition have been 
shown considerable decline. It was noted that TC, TG and 
LDL-C lowering activity of ethanolic root extract (400mg/kg) 
of Rubia cordifolia was more significant as compared to 
aqueous root extract of Rubia cordifolia. There was 
significant elevation in plasma HDL-C in Rubia cordifolia 
treated rats as compared to HFD rats, the efficacy of Rubia 
cordifolia extract in preventing the elevation seen in various 
components of lipid profile under experimentally induced 
hyperlipidemia. Flavonoids are reported to increase HDL-C 
concentration and decrease in LDL and VLDL levels in 
hypercholesteremic rats. Studies have shown that increased 
formation of free radical reactive oxygen species contribute 
to the progression of cardiovascular disease, reactive oxygen 
species induced cardiac disfunction and cardiac apoptosis. It 
was noted that different extract of Rubia cordifolia produce 
significantly higher total phenolic content. The high amount 
of phenols in extracts may explain their high antioxidant 
activities. Several phytoconstituents like glycosides, 
triterpenoids, saponins, alkaloids and flavonoids are known 
to have anti-hyperlipidemic properties. High fat diet In 
chosen in the present study, contain the common ingredients 
in our daily food. The high fat diet used this study contain 
saturated fatty acids which increases the activity of HMG CoA 
reductase, the rate determining enzyme in cholesterol 
biosynthesis. This may be due to higher availability of acetyl 
CoA, which stimulated the cholesterogenesis rate. 
Antihyperlipidemic activity observed with Atorvastatin 
(10mg/kg oral) and the Rubia cordifolia ethanolic extracts 
(400mg/kg) showed better activity thanRubia cordifolia 
aqueous extracts (200mg/kg). 
5. CONCLUSION  
The roots of Rubia cordifolia plants subjected to extractions 
in ethanol extract 14.7 % w/w and water extract 11.8 % 
w/w yielded respectively. Phytochemical analysis of the 
plant extracts showed different phytoconstituents viz. 
glycosides, phytosterols, triterpinoids, alkaloids and 
flavonoids. Several phytoconstituents like glycosides, 
triterpinoids, saponins, alkaloids and flavonoids are known 
to have anti-hyperlipidemic properties.  This study revealed 
that tested root extracts of Rubiacordifolia have significant 
antioxidant and antihyperlipidemic activity. In the present 
study, the pharmacological screening has led to the 
conclusion that, ethanolic and aqueous roots extracts of 
Rubia cordifolia have significant antihyperlipidemic activity. 
Hence it can be exploited as an antihyperlipidemic 
therapeutic agent or adjuvant in existing therapy for the 
treatment of hyperlipidemia. This study reveals that tested 
root extracts of Rubia cordifolia have significant free radical 
scavenging activity. The result of the present study suggests 
that the roots of Rubia cordifolia can be used as a source of 
antioxidants for the management of different diseases. This 
plant is an effective potential source of natural antioxidants. 
It has been concluded that the etanolic and aqueous root 
extracts of Rubia cordifolia have antioxidant activity in dose 
dependent manner.The broad spectrum antihyperlipidemic 
and antioxidant activities of the plant extracts may be due to 
their active constituents like tannins, alkaloids, flavonoids, 
glycosides, phytosterols, and triterpinoids. 
This study has demonstrated the antioxidant and 
antihyperlipidemic activities of roots extract from Rubia 
cordifolia plant. The antioxidant and antihyperlipidemic 
activity of the plant extract of Rubia cordifolia may play a 
significant role in the prevention and treatment of 
atherosclerosis and other cardiovascular diseases. Thus, 
Rubia cordifolia plant can be considered as an easily 
accessible source of natural antihyperlipidemic and 
antioxidant agents. 
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